Abstract
2111 Background: The combination of Ox, Irino and Cape has high potential for activity in gastrointestinal malignancies. Methods: Patients (pts) had solid tumors not amenable to curative therapy. Treatment: Ox intravenous (IV) days 1,8,15,22, followed by Irino IV days 1,8,15,22, and Cape orally bid Monday-Friday weeks1–4, repeated every 6 weeks. Primary endpoints: maximum tolerated dose (MTD), dose-limiting toxicity (DLT) and pharmacokinetic (PK) analysis. Response assessed q 2 cycles. Results: (see table) 22 pts enrolled: 13 males; median age 60, range 38–80; 11 colorectal cancer (ca); median 2 prior regimens. DLT at initial dose level 1A led to a protocol amendment lowering Cape dose. Peak SN38 concentrations of 10 ng/ml exceeded the IC50 doses reported for KB and L1210 tumor cells (0.37 and 3.6 ng/ml) (Kaneda, Cancer Res 1990). The mean peak ultrafilterable platinum was 0.75 +/- 0.17 μg/ml, exceeding the 0.5 μg/ml Ox concentration at which antitumor activity was observed against colon cancer using a hu...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
